Monogram Biosciences has a legacy of developing state-of-the-art, highly
reproducible, high-throughput assays in a clinical reference laboratory
setting. There is increasing demand from companies developing novel HCV agents
for assays to monitor susceptibility and resistance to inhibitors of the
polymerase (NS5B) and protease (NS3/4A). Monogram is well positioned to apply
its expertise to develop genotypic (sequencing) and phenotypic assays for HCV
viral resistance to drugs that act on polymerase (NS5B) and protease (NS3)
regions of the viral genome.
As is the case for HIV, it is likely that both genotypic and phenotypic assays
will be required to provide complementary information and that both assay
systems will become essential tools for HCV drug development and possibly for
patient management. Monogram has an established vision and plan for the
development of genotypic and phenotypic HCV resistance assays.
Currently, Monogram offers RUO validated NS5B genotype testing services to
clients for retrospective research studies, and is establishing partnerships
with companies that have active HCV programs for further development of
additional prototype assays.
If you are interested in further discussing Monogram's HCV efforts, please
contact:
Andrew Gale
Director, Pharma Collaborations
collaborations@monogrambio.com
Click here to
download the poster:
E Penuel, D Han, K Favero, E Lam, Y Liu, NT Parkin.
Development of a Rapid Phenotypic Susceptibility Assay for HCV Polymerase
Inhibitors.
For more information on Monogram assays, services and pricing, please contact us.
